drugset
drugset / Trial / NCT04572152

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

NCT04572152 ↗

Phase 1 Completed 23 enrolled Akeso
NaSequentialOpen-labelTreatment

Summary

This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors.

Timeline

Start
2020-12-07
Primary completion
2023-05-02
Completion
2023-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AK119 Monoclonal antibody — Intravenous
Subject Cadonilimab Monoclonal antibody — Intravenous

Indications

No indication recorded.